Doxorubicin paclitaxel in pretreated advanced small-cell lung cancer: a large real-life retrospective study
This real-world study suggests that the paclitaxel-doxorubicin combination provides some clinical activity in previously treated SCLC, including in platinum-resistant/refractory disease. Although toxicities were common, they were generally manageable. These findings support further investigation of this regimen with careful patient selection.
Authors
- Luca Campedel (ORCID: https://orcid.org/0000-0002-0046-0969)
- Camille Rolland Debord
- Baptiste Abbar (ORCID: https://orcid.org/0000-0002-5907-8131)
- Paul Gougis (ORCID: https://orcid.org/0000-0003-3064-7043)
- Coraline Cheuvart
- Clara Bourrachot
Institutions
- Inserm (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Immunité et Cancer (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre d'Immunologie et des Maladies Infectieuses (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tlcr-2025-653
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00